Royce & Associates LP lifted its position in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 33.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 458,335 shares of the company's stock after acquiring an additional 115,176 shares during the period. Royce & Associates LP owned approximately 0.15% of Stevanato Group worth $9,987,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also made changes to their positions in STVN. Van Berkom & Associates Inc. bought a new stake in Stevanato Group during the fourth quarter worth $39,000. PNC Financial Services Group Inc. lifted its position in shares of Stevanato Group by 1,457.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company's stock worth $123,000 after buying an additional 5,291 shares during the last quarter. US Bancorp DE boosted its stake in Stevanato Group by 17.9% in the fourth quarter. US Bancorp DE now owns 8,527 shares of the company's stock valued at $186,000 after buying an additional 1,295 shares in the last quarter. Marco Investment Management LLC bought a new position in Stevanato Group in the fourth quarter valued at about $203,000. Finally, Hardy Reed LLC raised its stake in Stevanato Group by 8.2% during the third quarter. Hardy Reed LLC now owns 11,077 shares of the company's stock worth $222,000 after acquiring an additional 840 shares in the last quarter.
Analyst Ratings Changes
STVN has been the topic of a number of research analyst reports. Bank of America raised their price target on shares of Stevanato Group from $24.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, December 13th. Morgan Stanley reaffirmed an "equal weight" rating and set a $23.00 target price (down previously from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. UBS Group dropped their price target on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research note on Friday, March 7th. William Blair restated an "outperform" rating on shares of Stevanato Group in a research report on Friday, March 7th. Finally, Wolfe Research started coverage on Stevanato Group in a report on Friday, December 13th. They issued an "outperform" rating and a $28.00 target price for the company. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, Stevanato Group currently has a consensus rating of "Moderate Buy" and an average price target of €27.75 ($30.16).
Read Our Latest Report on Stevanato Group
Stevanato Group Trading Up 3.9 %
NYSE STVN traded up €0.85 ($0.92) on Friday, reaching €22.52 ($24.48). The company had a trading volume of 328,073 shares, compared to its average volume of 350,109. The firm has a market cap of $6.82 billion, a price-to-earnings ratio of 47.91, a P/E/G ratio of 7.18 and a beta of 0.60. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group S.p.A. has a fifty-two week low of €16.56 ($18.00) and a fifty-two week high of €33.49 ($36.40). The business has a 50 day moving average of €21.04 and a two-hundred day moving average of €20.60.
Stevanato Group (NYSE:STVN - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting the consensus estimate of €0.20 ($0.22). The company had revenue of €352.68 million during the quarter, compared to analysts' expectations of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current year.
About Stevanato Group
(
Free Report)
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Read More
Before you consider Stevanato Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stevanato Group wasn't on the list.
While Stevanato Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
